Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Redhill Biopharma Ltd(RDHL)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for RDHL
09/25/2026: RDHL (1-star) is currently NOT-A-BUY. Pass it for now.
Redhill Biopharma Ltd is a specialized biotechnology company focused on developing and commercializing proprietary gastrointestinal and infectious disease treatments. While its commercial portfolio, featuring products like Talicia, provides a revenue base, the company has historically struggled to achieve profitability, leading to high cash burn and frequent reliance on external financing. Its primary investment story hinges on clinical success and market penetration of niche products, though these are balanced against significant competitive risks from larger pharmaceutical firms and potential shareholder dilution. Investors should carefully monitor liquidity, clinical trial data, and operational efficiency as key indicators of future performance. The stock may suit growth-oriented investors with high risk tolerance.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The potential for pipeline-driven growth is balanced against significant execution and financial risks. |
| Momentum investor | Mixed fit | Momentum is highly dependent on positive clinical trial readouts or commercial catalysts, which are infrequent. |
| Value investor | Weak fit | The company's history of losses and reliance on external capital makes traditional value metrics difficult to apply. |
| Dividend investor | Weak fit | The company does not pay dividends and focuses entirely on growth and survival. |
| Low-risk investor | Weak fit | High price volatility and binary clinical risks make this stock unsuitable for conservative portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks often experience extreme price swings based on news, clinical data, and market sentiment. |
| Valuation risk | Medium / high | Valuation is often speculative, tied more to future clinical potential than current cash flows. |
| Competition risk (Pharmaceutical giants) | High | Competing against established players like BHC or TAK presents significant barriers to market adoption. |
| Business quality | Medium | The company relies on a small portfolio, which concentrates operational risk. |
| Dividend income | Low / none | There is no income generation for shareholders. |
| Execution risk | High | Commercializing specialized drugs successfully requires navigating complex healthcare reimbursement landscapes. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -57.32% | Avg. Invested days 13 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.16M USD | Price to earnings Ratio - | 1Y Target Price 19000 |
Price to earnings Ratio - | 1Y Target Price 19000 | ||
Volume (30-day avg) 3.8M shares | Beta 4.95 | 52 Weeks Range 0.50 - 2.79 | Updated Date 09/25/2026 |
52 Weeks Range 0.50 - 2.79 | Updated Date 09/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Commercial Operations | Revenue generated from the sale of FDA-approved products like Talicia and Aemcolo. | The company generates cash primarily through sales of a few niche medications for gut-related issues. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE 1428.57 | Enterprise Value 413.10K | Price to Sales(TTM) 11.06 |
Enterprise Value 413.10K | Price to Sales(TTM) 11.06 | ||
Enterprise Value to Revenue 1.44 | Enterprise Value to EBITDA 0.3 | Shares Outstanding 6.08M | Shares Floating 4.20M |
Shares Outstanding 6.08M | Shares Floating 4.20M | ||
Percent Insiders - | Percent Institutions 5.19 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Redhill Biopharma Ltd
Exchange NASDAQ | Headquarters - | ||
IPO Launch date 2013-01-07 | Co-Founder, Chairman & CEO Mr. Dror Ben-Asher | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 13 | Website https://www.redhillbio.com |
Full time employees 13 | Website https://www.redhillbio.com | ||
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; Rebyota, a microbiota-based therapy for prevention of recurrent Clostridioides difficile infection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. It also commercializes Clenpiq, a ready-to-drink low-volume bowel preparation. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.